Combination of DPP-IV inhibitors and compounds modulating 5-HT3 and/or 5-HT4 receptors

Details for Australian Patent Application No. 2005261778 (hide)

Owner Novartis AG

Inventors Villhauer, Edwin Bernard

Agent Davies Collison Cave

Pub. Number AU-A-2005261778

PCT Pub. Number WO2006/005613

Priority 60/588,011 14.07.04 US

Filing date 13 July 2005

Wipo publication date 19 January 2006

International Classifications

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 31/404 (2006.01)

Event Publications

1 February 2007 PCT application entered the National Phase

  PCT publication WO2006/005613 Priority application(s): WO2006/005613

24 September 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005261779-Electrical pressure contact

2005261777-Process for the preparation of 4,4-difluoro-3-oxobutanoic acid esters